Literature DB >> 11381277

The 2000 Canadian recommendations for the management of hypertension: Part one--therapy.

F A McAlister1, M Levine, K B Zarnke, N Campbell, R Lewanczuk, F Leenen, S Rabkin, J M Wright, J Stone, R D Feldman, M Lebel, G Honos, G Fodor, E Burgess, S Tobe, P Hamet, R Herman, J Irvine, B Culleton, R Petrella, R Touyz.   

Abstract

OBJECTIVE: To provide updated, evidence-based recommendations for the therapy of hypertension in adults. OPTIONS: For patients with hypertension, there are a number of lifestyle manoeuvres and antihypertensive agents that may control blood pressure. Randomized trials evaluating first- line therapy with thiazides, beta-adrenergic antagonists, angiotensin-converting enzyme inhibitors, calcium channel blockers, alpha-blockers, centrally acting agents or angiotensin II receptor antagonists were reviewed. OUTCOMES: The health outcomes considered were changes in blood pressure, cardiovascular morbidity, and cardiovascular and/or all-cause mortality rates. Economic outcomes were not considered due to insufficient evidence. EVIDENCE: Medline searches were conducted from the period of the last revision of the Canadian Recommendations for the Management of Hypertension (May 1998 to October 2000). Reference lists were scanned, experts were polled, and the personal files of the subgroup members and authors were used to identify other studies. All relevant articles were reviewed and appraised, using prespecified levels of evidence, by content experts and methodological experts. VALUES: A high value was placed on the avoidance of cardiovascular morbidity and mortality. BENEFITS, HARMS, AND COSTS: Various lifestyle manoeuvres and antihypertensive agents reduce the blood pressure of patients with sustained hypertension. In certain settings, and for specific classes of drugs, blood pressure lowering has been associated with reduced cardiovascular morbidity and/or mortality. RECOMMENDATIONS: The present document contains detailed recommendations pertaining to all aspects of the therapy of patients with hypertension, including lifestyle modifications proven to lower blood pressure, treatment thresholds, target blood pressures, choice of agents in various settings and strategies to enhance adherence. Lower thresholds for blood pressure treatment are advocated for people with other cardiovascular risk factors or established hypertensive target organ damage. Implicit in the recommendations for therapy is the principle that treatment should be individualized for each patient and the choice of agent should be dictated by coexistent conditions. For the treatment of uncomplicated essential hypertension, thiazides, beta-adrenergic antagonists, angiotensin-converting enzyme inhibitors or calcium channel blockers may be appropriate, depending on individual circumstances. VALIDATION: All recommendations were graded according to strength of the evidence and voted on by the Canadian Hypertension Recommendations Working Group. Only those recommendations achieving high levels of consensus are reported here. These guidelines will be updated annually.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11381277

Source DB:  PubMed          Journal:  Can J Cardiol        ISSN: 0828-282X            Impact factor:   5.223


  19 in total

1.  2001 Canadian hypertension recommendations. What has changed?

Authors: 
Journal:  Can Fam Physician       Date:  2002-10       Impact factor: 3.275

2.  The 2001 Canadian hypertension recommendations: take-home messages.

Authors:  Norman R C Campbell; Denis Drouin; Ross D Feldman
Journal:  CMAJ       Date:  2002-09-17       Impact factor: 8.262

3.  The 2006 Canadian Hypertension Education Program recommendations for the management of hypertension: Part I--Blood pressure measurement, diagnosis and assessment of risk.

Authors:  B R Hemmelgarn; Finlay A McAlister; Steven Grover; Martin G Myers; Donald W McKay; Peter Bolli; Carl Abbott; Ernesto L Schiffrin; George Honos; Ellen Burgess; Karen Mann; Thomas Wilson; Brian Penner; Guy Tremblay; Alain Milot; Arun Chockalingam; Rhian M Touyz; Sheldon W Tobe
Journal:  Can J Cardiol       Date:  2006-05-15       Impact factor: 5.223

4.  The 2006 Canadian Hypertension Education Program recommendations for the management of hypertension: Part II - Therapy.

Authors:  N A Khan; Finlay A McAlister; Simon W Rabkin; Raj Padwal; Ross D Feldman; Norman Rc Campbell; Lawrence A Leiter; Richard Z Lewanczuk; Ernesto L Schiffrin; Michael D Hill; Malcolm Arnold; Gordon Moe; Tavis S Campbell; Carol Herbert; Alain Milot; James A Stone; Ellen Burgess; B Hemmelgarn; Charlotte Jones; Pierre Larochelle; Richard I Ogilvie; Robyn Houlden; Robert J Herman; Pavel Hamet; George Fodor; George Carruthers; Bruce Culleton; Jacques Dechamplain; George Pylypchuk; Alexander G Logan; Norm Gledhill; Robert Petrella; Sheldon Tobe; Rhian M Touyz
Journal:  Can J Cardiol       Date:  2006-05-15       Impact factor: 5.223

Review 5.  Microalbuminuria in diabetes mellitus.

Authors:  Sheldon W Tobe; Philip Alan McFarlane; David Malcolm Naimark
Journal:  CMAJ       Date:  2002-09-03       Impact factor: 8.262

Review 6.  The use of calcium antagonists in the treatment of hypertensive persons with kidney disease.

Authors:  Sheldon Tobe; Murray Epstein
Journal:  Curr Hypertens Rep       Date:  2002-06       Impact factor: 5.369

7.  Randomized controlled trials: do they have external validity for patients with multiple comorbidities?

Authors:  Martin Fortin; Jonathan Dionne; Geneviève Pinho; Julie Gignac; José Almirall; Lise Lapointe
Journal:  Ann Fam Med       Date:  2006 Mar-Apr       Impact factor: 5.166

Review 8.  Evolution of Blood Pressure Clinical Practice Guidelines: A Personal Perspective.

Authors:  Paul K Whelton
Journal:  Can J Cardiol       Date:  2019-02-27       Impact factor: 5.223

9.  Markers of loss of control of hypertension.

Authors:  Richard Ian Casson; Will D King; Noah Marshall S Godwin
Journal:  Can Fam Physician       Date:  2003-10       Impact factor: 3.275

Review 10.  The 2008 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2 - therapy.

Authors:  Nadia A Khan; Brenda Hemmelgarn; Robert J Herman; Simon W Rabkin; Finlay A McAlister; Chaim M Bell; Rhian M Touyz; Raj Padwal; Lawrence A Leiter; Jeff L Mahon; Michael D Hill; Pierre Larochelle; Ross D Feldman; Ernesto L Schiffrin; Norman R C Campbell; Malcolm O Arnold; Gordon Moe; Tavis S Campbell; Alain Milot; James A Stone; Charlotte Jones; Richard I Ogilvie; Pavel Hamet; George Fodor; George Carruthers; Kevin D Burns; Marcel Ruzicka; Jacques dechamplain; George Pylypchuk; Robert Petrella; Jean-Martin Boulanger; Luc Trudeau; Robert A Hegele; Vincent Woo; Phil McFarlane; Michel Vallée; Jonathan Howlett; Peter Katzmarzyk; Sheldon Tobe; Richard Z Lewanczuk
Journal:  Can J Cardiol       Date:  2008-06       Impact factor: 5.223

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.